9100 POSTER Erlotinib in Previously Treated NSCLC – a Critical Appraisal Based on Monoinstitutional Experience von Trojniak, M.P, Palozzo, A.C, di Maggio, A, Mazurek, M, Jirillo, A

Volltext

Budget Impact Analysis of Ipilimumab for the Treatment of Advanced Melanoma in the Veneto Region, Italy von Adami, S, Aiello, A, Palozzo, A.C, Magrì, M.R, Visentin, E, Chiarion, V, Michelon, A, Alberti, C, Maran, P.R, Saugo, M, Scroccaro, G

Volltext

Sunitinib in Advanced RCC: Cost-Effectiveness Evaluation Based on Clinical Practice von Trojniak, M.P., Cappetta, A., Palozzo, A.C., Imbevaro, S., Rescigno, P., Jirillo, A.

Volltext

Post-Progression Survival After Erlotinib Treatment in Patients with Advanced Nsclc von Trojniak, M.P., Palozzo, A.C., Imbevaro, S., Rescigno, P., Pastorelli, D., Jirillo, A.

Volltext

A New Proposal of Drug Pricing Based on Value for Effectiveness in Real Practice Oncology von Jirillo, A., Trojniak, M.P., Imbevaro, S., Rescigno, P., Pastorelli, D., Palozzo, A.C.

Volltext

PCN40 - Budget Impact Analysis of Ipilimumab for the Treatment of Advanced Melanoma in the Veneto Region, Italy von Adami, S, Aiello, A., Palozzo, A.C., Magrì, M.R., Visentin, E., Chiarion, V., Michelon, A., Alberti, C., Maran, P.R., Saugo, M., Scroccaro, G.

Volltext

Neurohypophysis NMR Signal Anomalies: A Report of Two Cases von Greggio, N.A., Amaina, A., Lorusso, A., Manara, R., Palozzo, A.C.

Volltext